share_log

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY

新阿姆斯特丹製藥公司第一季度每股收益爲1.06美元,同比增長0.51美元
Benzinga ·  05/09 21:04

First Quarter Financial Results

第一季度財務業績

  • Cash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on offering and warrant exercises partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.
  • Revenue: NewAmsterdam recognized $1.4 million in revenue for the quarter ended March 31, 2024, compared to $8.6 million in the same period in 2023. This decrease was primarily due to the recognition of license revenue related to a clinical development milestone in the quarter ended March 31, 2023 while no clinical development milestones were achieved in the same period in 2024.
  • Research and Development ("R&D") Expenses: R&D expenses were $42.4 million in the quarter ended March 31, 2024, compared to $40.4 million for the same period in 2023. This increase was primarily due to an increase in clinical expenses related to the Company's ongoing Phase 3 clinical trials, partially offset by a decrease in manufacturing costs.
  • Selling, General and Administrative ("SG&A") Expenses: SG&A expenses were $14.5 million in the quarter ended March 31, 2024, compared to $8.1 million for the same period in 2023. This increase was primarily due to an increase in personnel costs related to expansion of the team to support the growth of the organization and investments in capabilities to support the Company's planned commercial launch of obicetrapib, if approved.
  • Net loss: Net loss for the quarter ended March 31, 2024 was $93.8 million, or $1.06 per diluted share, compared to net loss of $42.0 million, or $0.51 per diluted share, for the same period in 2023.
  • 現金狀況:截至2024年3月31日,新阿姆斯特丹記錄的現金爲4.811億美元,而截至2023年12月31日爲3.405億美元。現金的增加主要是由後續發行和認股權證行使的收益部分被與研發成本相關的現金流出所抵消,因爲公司繼續開發obicetrapib,以及爲支持公司不斷壯大的組織而增加的銷售、一般和管理開支支出。
  • 收入:截至2024年3月31日的季度,新阿姆斯特丹確認的收入爲140萬美元,而2023年同期爲860萬美元。這一下降主要是由於在截至2023年3月31日的季度中確認了與臨床開發里程碑相關的許可收入,而在2024年同期沒有實現臨床開發里程碑。
  • 研發(“研發”)費用:截至2024年3月31日的季度,研發費用爲4,240萬美元,而2023年同期爲4,040萬美元。這一增長主要是由於與公司正在進行的3期臨床試驗相關的臨床費用增加,但部分被製造成本的下降所抵消。
  • 銷售、一般和管理(“SG&A”)費用:截至2024年3月31日的季度,銷售和收購支出爲1,450萬美元,而2023年同期爲810萬美元。這一增長主要是由於與擴大團隊以支持組織發展相關的人員成本增加,以及對能力的投資,以支持公司計劃在商業上推出obicetrapib(如果獲得批准)。
  • 淨虧損:截至2024年3月31日的季度淨虧損爲9,380萬美元,攤薄每股虧損1.06美元,而2023年同期的淨虧損爲4,200萬美元,攤薄每股虧損0.51美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論